Please wait while we load the requested 10-K report or click the link below:
https://last10k.com/sec-filings/report/715446/000151316220000009/form10k.htm
April 2022
March 2022
December 2021
October 2021
October 2021
June 2021
May 2021
April 2021
March 2021
January 2021
Document And Entity Information - USD ($) | 12 Months Ended | ||
---|---|---|---|
Oct. 31, 2019 | Jan. 08, 2020 | Apr. 30, 2019 | |
Document Information Line Items | |||
Entity Registrant Name | Anixa Biosciences Inc | ||
Document Type | 10-K | ||
Current Fiscal Year End Date | --10-31 | ||
Entity Common Stock, Shares Outstanding | 20,821,204 | ||
Entity Public Float | $ 72,311,537 | ||
Amendment Flag | false | ||
Entity Central Index Key | 0000715446 | ||
Entity Current Reporting Status | Yes | ||
Entity Voluntary Filers | No | ||
Entity Filer Category | Non-accelerated Filer | ||
Entity Well-known Seasoned Issuer | No | ||
Document Period End Date | Oct. 31, 2019 | ||
Document Fiscal Year Focus | 2019 | ||
Document Fiscal Period Focus | FY | ||
Entity Small Business | true | ||
Entity Emerging Growth Company | false | ||
Entity Shell Company | false | ||
Entity Ex Transition Period | false | ||
Entity Interactive Data Current | Yes |
Please wait while we load the requested 10-K report or click the link below:
https://last10k.com/sec-filings/report/715446/000151316220000009/form10k.htm
Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were removed , added and changed by Anixa Biosciences Inc.
Anixa Biosciences Inc's Definitive Proxy Statement (Form DEF 14A) filed after their 2020 10-K Annual Report includes:
Rating
Learn More![]()
Cash provided by financing activities was approximately $5,734,000, resulting from the sale of 1,363,872 shares of common stock in an at-the-market equity offering of approximately $5,527,000, the proceeds from exercise of stock options of approximately $122,000, the proceeds from settlement of a shareholder derivative complaint of approximately $45,000 and the proceeds from the sale of common stock pursuant to employee stock purchase plan of approximately $39,000.
The net loss attributable to noncontrolling interest, representing Wistar's 5% ownership interest in Certainty's net loss, decreased by approximately $75,000 to approximately $172,000 in fiscal year 2019, from approximately $247,000 in fiscal year 2018, as Certainty's net loss decreased.
Accordingly, the performance obligations from these licenses were satisfied and 100% of the revenue was recognized upon execution of the license agreement.
As such, the performance obligation is satisfied and revenue is recognized upon the execution of the agreement.
The decrease in research and development expenses was primarily due to a decrease of approximately $1,410,000 in employee stock option compensation expense, a decrease in employee stock award compensation expense of approximately $351,000 and a decrease in license fees of approximately $190,000, offset by an increase in Certainty's outside research and development expense, excluding license expense, primarily related to its collaboration agreement with Moffitt of approximately $344,000, an increase in Anixa Diagnostics' outside research and development expense, excluding license expense, primarily related to its agreement with our development partner, ResearchDx, of approximately $193,000 and an increase in depreciation expense of approximately $30,000.
Research and development expenses are...Read more
The decrease in Certainty's net...Read more
We can give no assurance...Read more
The impairment in carrying amount...Read more
The impairment in carrying amount...Read more
As a result, our cash,...Read more
Further, we have an additional...Read more
General and administrative expenses decreased...Read more
Additionally, the sale of equity...Read more
Financial Statements, Disclosures and Schedules
Inside this 10-K Annual Report
Material Contracts, Statements, Certifications & more
Anixa Biosciences Inc provided additional information to their SEC Filing as exhibits
Ticker: ANIX
CIK: 715446
Form Type: 10-K Annual Report
Accession Number: 0001513162-20-000009
Submitted to the SEC: Thu Jan 09 2020 4:16:35 PM EST
Accepted by the SEC: Thu Jan 09 2020
Period: Thursday, October 31, 2019
Industry: Medical Laboratories